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Abstract Gene expression is influenced by mechanisms regulat-
ing mRNA degradation. Knowledge on regulatory RNA elements
involved and on proteins interacting with them is still limited. A
33 nucleotide (nt) region of the 55 kDa tumor necrosis factor
receptor (TNFR-55) mRNA, previously reported by us to engage
in such interaction with proteins from U-937 cells, exhibits
homology to a 38 nt regulatory region of the glucose transporter
GLUT-1 mRNA. Labeled RNA fragments comprising these two
regions bind similar sets of proteins. Upon phorbol ester-induced
differentiation into macrophage-like cells, protein binding to both
fragments is changed similarly. Furthermore, both compete with
each other for protein binding. This suggests that GLUT-1 and
TNFR-55 RNA share a novel protein binding RNA motif
involved in regulation of their half life.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Gene expression is regulated in part by changes in RNA
stability [1]. The mechanisms that a¡ect the half life of a
certain transcript involve interaction between a protein bind-
ing sequence element and the respective trans-acting factor.
Cis-acting elements within the mRNAs have been identi¢ed
and characterized to very di¡erent extents, varying from allo-
cation within several hundred nucleotides, frequently the 3P-
UTR, to identi¢cation of the minimum target structure for
proteins that bind to them (e.g. [2^4]). A well-characterized
example for regulation of RNA degradation is the interaction
between the iron responsive element (IRE) in the 3P-UTR of
the transferrin receptor mRNA and the protein that binds to
it (reviewed in [5]), thereby protecting the RNA from endo-
nucleolytic attack [6]. Another type of regulatory domains are
the AU-rich elements (AREs) found in the 3P-UTR of many
cytokine and oncogene mRNAs [7]. Transcripts containing
AREs often are short-lived, and AREs are thought to play
a key role for their stability by interacting with binding fac-
tors, some of which have been puri¢ed [8] or cloned [9^12].
Recently we observed that a change in RNA stability con-
tributes to regulation of expression of the 55 kDa tumor ne-
crosis factor receptor (TNFR-55) [13]. By triggering this re-
ceptor, its ligand TNF activates signal transduction pathways
which cause a multiplicity of e¡ects in the various target cells.
Thereby TNFR-55 plays a central role in orchestrating in-
£ammatory responses [14]. Its expression is tightly controlled,
keeping the cell surface number of receptors in the range of
hundreds to a few thousands per cell. The necessity to restrain
its number is apparent from the drastic e¡ects that TNF can
have in the organisms as well as on individual cells. Most
notably, overexpression of TNFR-55 can lead to ligand-inde-
pendent oligomerization, signaling and, consequently, cell
death [15].
We have reported that in myelomonocytic cell lines cell
surface expression of TNFR-55 as well as the amount of its
mRNA are down-regulated during phorbol ester-induced dif-
ferentiation into macrophage-like cells [16]. The decrease was
largely due to destabilization of the mRNA in the di¡erenti-
ated cells [13]. A concomitant change in the binding of cyto-
plasmic proteins to the receptor RNA was noted. The protein
binding region, located within 33 nt of the coding sequence,
does not contain an ARE and no apparent homologies to the
IRE or other classical protein binding RNA regions. Re-
cently, distinct regions in the bovine and human glucose trans-
porter GLUT-1 mRNAs were reported to bind proteins and
to a¡ect RNA stability [17^19]. We observed a signi¢cant
homology between the protein binding regions of the
GLUT-1 and TNFR-55 mRNAs and provide evidence that
the protein binding regions of both RNAs can interact with
the same or overlapping sets of proteins.
2. Materials and methods
2.1. Cell culture
The human histiocytic lymphoma cell line U-937 [20] was obtained
from the ATCC and grown in RPMI 1640 medium supplemented
with antibiotics and 5% fetal calf serum. Di¡erentiation into macro-
phage-like cells was induced by incubation with the phorbol ester
12-O-tetradecanoylphorbol-13-acetate (TPA) (10 nM) for 48 h [16].
2.2. Templates used in in vitro transcription
Full length RNA of the TNFR-55 was transcribed from cDNA
clone E13 in Bluescript KS plasmid [21]. Templates for the generation
of fragments of human GLUT-1 mRNA (as speci¢ed in Fig. 2) were
obtained by reverse transcription PCR using RNA from TPA-di¡er-
entiated U-937 cells. To enable in vitro transcription from the cDNA
templates, sense primers contained the T7 RNA polymerase start site
(5P-T7, for details see [13]). Templates for the 33 nt and 38 nt frag-
ments of TNFR-55 and GLUT-1 RNA were prepared by annealing
and extension of overlapping primer pairs (TNFR-55/sense: 5P-T7-
CAAGGAAAATATAT, antisense: 5P-CGAATTATTTTGAGGGT-
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GGATATATTTTCCTTGCCCT; GLUT-1/sense: 5P-T7-TCTCTTC-
CTACCCAAC; antisense: 5P-TAAAGAAAGATTAATTTGAGTG-
GTTGGGTAGGAAGAGA). Nucleotide positions in the cDNAs
are given according to GenBank accession numbers X55313
(TNFR-55), K03195 (human GLUT-1), M23384 (murine GLUT-1)
and M60448 (bovine GLUT-1). RNA of the neomycin resistance
gene and a 112 nt fragment of 18 S rRNA were transcribed from
the control templates supplied in the T7 in vitro transcription kits
from Boehringer Mannheim and Ambion, respectively.
2.3. In vitro transcription
RNAs were synthesized according to the instructions of the T3/T7
in vitro transcription kit (Boehringer Mannheim) or the T7-MEGA-
shortskript kit (Ambion). After template digestion the RNAs were
extracted with phenol/chloroform, precipitated, reconstituted with au-
toclaved water and stored at 70‡C (for further details see [13]).
For the synthesis of labeled RNA, 50 WCi of [K-32P]UTP (400 Ci/
mmol, Hartmann Analytic) and unlabeled UTP were included in the
reaction mixture at a ¢nal concentration of 24 WM. Following phenol/
chloroform extraction, transcription mixtures were passed through a
NucTrap push column (Stratagene) to remove free nucleotides. In the
electrophoretic mobility shift assays (see below), similar amounts of
radioactivity (0.5^1.5U105 cpm) were used, corresponding to 2^10
fmol of full length TNFR-55 or GLUT-1 3P-UTR transcripts and
250^750 fmol of the 33 or 38 nt RNA fragments.
2.4. Preparation of cytoplasmic extracts and detection of protein-RNA
complexes
Preparation of cytoplasmic extracts and electrophoretic mobility
shift assays were carried out as described [13]. Brie£y, cells were lysed
in 100 Wl of lysis bu¡er (25 mM Tris-HCl, pH 7.9, 15 mM KCl, 0.6%
(v/v) Nonidet P-40, 0.5 mM EDTA, 10 Wg/ml aprotinin, 10 Wg/ml
leupeptin, 10 Wg/ml pepstatin, 2 mM benzamidine and 0.2 mM dithio-
threitol). The cytoplasmic extract was cleared by centrifugation and
aliquots were stored at 370‡C. The radiolabeled RNA probes (see
above) were incubated with cytoplasmic extracts (3 Wg protein per
sample) in 25 mM Tris-HCl, pH 7.9, 15 mM KCl, 5% (v/v) glycerol,
0.2 mM dithiothreitol, 0.5 mM EDTA and 4 Wg tRNA in a total
volume of 20 Wl for 10 min at 30‡C. The mixture was then digested
with RNase T1 and electrophoresed on a non-denaturing polyacryl-
amide gel. Competition experiments with unlabeled RNAs and UV
cross-linking of RNA-protein complexes were performed as described
[13].
3. Results
As shown previously, radiolabeled TNFR-55 mRNA forms
speci¢c complexes with cytoplasmic proteins from U-937 cells
induced to di¡erentiate into macrophage-like cells by phorbol
esters ([13] and Fig. 1A). To disclose a possible relationship of
this protein-RNA interaction to already identi¢ed RNA bind-
ing proteins and their target sequences, several RNAs known
to be regulated on the level of stability were tested for com-
petition with the TNFR-55 RNA. As shown in Fig. 1A, the
3P-UTR of GLUT-1 RNA e¡ectively competed with TNFR-
55 RNA in complex formation. An unrelated transcript, of
the neomycin resistance gene, dit not compete, indicating that
the e¡ect of the GLUT-1 RNA was speci¢c (Fig. 1A). The
labeled GLUT-1, 3P-UTR also formed complexes with protein
(Fig. 1B). Furthermore, unlabeled TNFR-55 transcript com-
peted with the GLUT-1 RNA for protein binding. These data
suggest that the two mRNAs are recognized by the same or
overlapping sets of proteins. The 3P-UTR of the GLUT-1
mRNA contains an AUUUA motif within an ARE [22] and
two additional regions most recently reported to be implicated
in regulation of its stability [17,18]. One of them (G-38 in Fig.
2) harbors a stretch of nucleotides with signi¢cant homology
to the 33 nt protein binding region of the TNFR-55 mRNA
(T-33 in Fig. 2). To locate the sequence elements within the
GLUT-1 3P-UTR responsible for binding U-937 proteins,
fragments of the transcript were tested for their competition
with labeled GLUT-1 3P-UTR RNA. Only fragment B, which
contained the G-38 region, e¡ectively competed in formation
of all four complexes (Fig. 3). Fragment C competed only
weakly in formation of complexes CG and DG, and fragment
A did not compete.
To address the protein binding capacity of the G-38 region
directly, the corresponding 38 nt labeled RNA fragment was
synthesized. Its complex formation with U-937 proteins was
compared to that of TNFR-55 RNA (full length or 33 nt
fragment) upon cross-linking by UV light to allow direct com-
parison of their sizes in SDS-PAGE. As shown in Fig. 4, all
three RNAs underwent complex formation with proteins from
untreated as well as from TPA-di¡erentiated cells. Complex
formation with the di¡erent RNAs resembled each other in
two ways. (1) The capacity of proteins to bind G-38 RNA, as
well as TNFR-55 RNA and its T-33 region, changes upon
TPA-induced di¡erentiation of the cells. Incubation of both
RNA species with proteins from the di¡erentiated cells re-
sulted in much stronger formation of the larger complexes.
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Fig. 1. Formation of complexes between proteins from U-937 cells
and transcripts of TNFR-55 and GLUT-1. 32P-labeled RNAs tran-
scribed from a human full length TNFR-55 cDNA (A) or from a
human GLUT-1 cDNA fragment (nt 1650^2540 of its 3P-UTR) (B)
were incubated with extracts from U-937 cells cultured in the pres-
ence of TPA (10 nM) for 48 h. Where indicated, unlabeled RNA of
TNFR-55, GLUT-1 3P-UTR, or the neomycin resistance gene (Neo-
R) was included in the incubation at 50-, 200-, or 800-fold molar
excess. Following RNase T1 digestion, the samples were analyzed
by electrophoresis through a 5% non-denaturating polyacrylamide
gel (see Section 2).
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(2) The complexes formed with the G-38 RNA fragment and
full length TNFR-55 RNA or its T-33 fragment were of sim-
ilar though not identical sizes: the protein binding element of
TNFR-55 RNA yielded complexes of approximately 55 and
75^80 kDa in the same manner as the full length transcript
[13], and an additional complex of about 120 kDa. Sizes of
complexes with G-38 were about 51, 54, 73, 93, and 130 kDa.
Considering that these di¡erences could be due to di¡erences
in the way electrophoretic mobility of the complexes is af-
fected by the GLUT-1 versus TNFR-55 RNA components,
these results may indicate that the homologous fragments of
TNFR-55 and GLUT-1 mRNA interact with the same cellu-
lar proteins. In support of this notion, speci¢c cross-competi-
tion as observed between the full length TNFR-55 RNA and
GLUT-1 3P-UTR (Fig. 1) was apparent between the two pro-
tein binding RNA fragments (Fig. 5).
4. Discussion
Regulation of mRNA half life contributes to altered gene
expression in in£ammation, development and other situations
of dramatic changes within an organism [1]. Knowledge on
regulatory RNA sequence and factors interacting with them is
still limited. We have previously observed destabilization of
TNFR-55 mRNA during the TPA-induced di¡erentiation of
the histiocytic lymphoma cell line U-937 into macrophage-like
cells and characterized the interaction between proteins from
those cells and a 33 nt region of TNFR-55 mRNA [13]. The
results of the present study suggest that the same or overlap-
ping sets of proteins from U-937 cells can interact with
TNFR-55 RNA and GLUT-1 RNA.
GLUT-1, the major glucose transporter molecule of the
brain and of erythrocytes, can be expressed in a variety of
other tissues. Its induction in macrophages exposed to endo-
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Fig. 2. Homology between protein binding regions of TNFR-55 and GLUT-1 mRNAs. Scheme of RNAs and positions of the 33 nt protein
binding region of TNFR-55 mRNA ([13], designated T-33 in scheme), the 38 nt protein binding region of GLUT-1 RNA ([17] and this study,
designated G-38) and its AREs ([18,22], designated ARE1 and ARE2, respectively). The sequence of the human G-38 region is compared to
the T-33 region of TNFR-55 RNA, and to murine and bovine G-38. Asterisks (*) indicate identical base residues, (^) indicates a gap in the
alignment. Also shown are the locations of GLUT-1 RNA fragments A to C used in competition experiments (Fig. 3).
Fig. 3. Competition for protein binding between the GLUT-1 3P-
UTR and fragments thereof. Protein-RNA complexes were analyzed
as in Fig. 1, using extracts from TPA-treated U-937 cells and la-
beled GLUT-1 3P-UTR. Unlabeled RNA fragments of the GLUT-1
3P-UTR (see Fig. 2, fragment A, nt 1650^2182; fragment B, nt
2183^2363; fragment C, nt 2344^2540) were added at the indicated
molar excess.
Fig. 4. Cross-linking analysis of the complexes formed with TNFR-
55 and GLUT-1 RNA. Full length TNFR-55 RNA and the 33 nt
TNFR-55 and 38 nt GLUT-1 RNA fragments were incubated with
extracts from U-937 cells cultured for 48 h in the absence (con) or
presence (TPA) of 10 nM TPA. After RNase T1 digestion, the sam-
ples were UV cross-linked for 15 min and analyzed by SDS-PAGE
(10% acrylamide). The positions of molecular weight markers are in-
dicated.
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toxin [23] and in ¢broblastoid cells treated with TNF [22,24]
suggests that it plays a major role in the changes in glucose
metabolism during in£ammation. Mechanisms controlling its
expression include alterations in RNA stability (reviewed in
[25]).
In transfection studies the GLUT-1 3P-UTR conferred in-
stability to a stable reporter transcript. The chimeric RNA
could be stabilized by TNF treatment [25]. Di¡erent regions
of the GLUT-1 3P-UTR appear to contribute to regulation of
its stability. Up-regulation of murine GLUT-1 mRNA half
life after stimulation of 3T3-L1 cells was correlated to forma-
tion of a 44 kDa complex between the GLUT-1 3P-UTR and
the adenosine-uridine binding factor (AUBF), and has been
suggested to involve an ARE containing and AUUUA motif
(ARE2 in Fig. 2) [22]. However, experiments with di¡erent
RNA fragments indicated that a distinct ARE, located more
upstream in the 3P-UTR (ARE1 in Fig. 2) engaged in com-
plexes of 44 kDa [17,18], and according to a recent report the
elav-like RNA binding protein Hel-N1 can bind to that region
[26]. The results presented in Fig. 3 and additional experi-
ments employing labeled RNA fragments failed to provide
evidence that proteins from U-937 cells bind to the ARE1
region. The weak competition of fragment C in formation
of complexes CG and DG (Fig. 3) indicates that binding of
some proteins to the ARE2 region may occur. Yet the major
domain for binding of proteins from U-937 cells is located
within the G-38 region (Figs. 3 and 4).
That region is highly conserved among several mammalian
species and contains the sequence homology to the protein
binding region of the TNFR-55 RNA. The corresponding
region of bovine GLUT-1 RNA has been identi¢ed as the
RNA component of an 88 kDa complex between part of
the bovine GLUT-1 3P-UTR and proteins from C6 rat glio-
blastoma cells [17]. Most recently, increased expression of a
reporter gene upon its fusion with a partial cDNA of the
bovine GLUT-1 3P-UTR was abolished by deleting 10 nt of
that region [19], demonstrating its functional importance. In
another study [18], evidence was provided that a sequence
within the corresponding region of that human GLUT-1 tran-
script (nt 2186^2203) participates in forming 120 kDa com-
plexes with proteins from human brain tumor extracts.
We show that an RNA fragment encompassing the human
38 nt GLUT-1 region (2183^2220) is su⁄cient to form several
complexes with cytosolic proteins from U-937 cells (Figs. 4
and 5). Taking into account that due to di¡erent experimental
setups these complexes contain RNA of 38 nt versus 52 nt in
the studies of Tsukamoto et al. [18,19], it is likely that the 130
kDa and 93 kDa complexes detected by us correspond to the
120 and V90 kDa complexes in those studies. Of note, it
appears that the monocytic cells used in our study contain
additional GLUT-1 RNA binding proteins whose relation to
the proteins detected by others is not clear at present.
The GLUT-1 mRNA is strongly induced in TPA-di¡eren-
tiated U-937 cells (not shown). Though the barely detectable
level in undi¡erentiated cells precluded direct comparison of
mRNA half lives, the long half life in di¡erentiated cells (V3
h, not shown), as compared to the basal half life in other cells,
notably also in myeloid precursors ([25] and references there-
in), and the evidence for a regulatory function of the respec-
tive RNA region [19] lead us to assume involvement of the
observed changes in protein-RNA interaction in regulation of
GLUT-1 RNA degradation in U-937 cells.
The observations that TNFR-55 and GLUT-1 RNAs yield
similar complexes with proteins from undi¡erentiated U-937
cells, that TPA-induced di¡erentiation causes similar changes
in protein binding to both RNAs, and that both compete with
each other for binding proteins suggest that they might inter-
act with the same cellular proteins. Yet, while GLUT-1
mRNA is induced during TPA-induced di¡erentiation, the
TNFR-55 mRNA is destabilized and down-regulated [13].
Possibly this inverse regulation is related to di¡erences not
re£ected in the formation of protein-RNA complexes as ob-
served here. Thus the proteins may serve as adaptors for dif-
ferent additional factors regulating RNA stability. Further-
more, the positioning of the homologous protein binding
element within the respective transcript, in the N-terminal
part of the coding region for TNFR-55 but in the 3P-UTR
for GLUT-1 may be crucial.
In summary, it is suggested that the protein binding regions
of the TNFR-55 and GLUT-1 RNAs contain a novel regu-
latory RNA element which may be present in additional, as
yet unidenti¢ed transcripts. In the U-937 model of macro-
phage di¡erentiation, the observed changes in the interaction
of proteins with that regulatory element may coordinately
a¡ect the half life of a set of mRNAs, thereby contributing
to altered gene expression. Gaining knowledge on the function
of the proteins interacting with that element will be a major
goal of future investigation.
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Fig. 5. Cross-competition between the protein binding regions of TNFR-55 and GLUT-1 mRNA. Complexes formed between extracts from
TPA-treated U-937 cells and the labeled fragments of TNFR-55 RNA (33 nt) or GLUT-1 RNA (38 nt) were analyzed as described in Fig. 4.
The same RNA fragments were included in the incubation as unlabeled competitors at a 50- to 500-fold molar excess (irr. : irrelevant RNA,
consisting of 112 nt of the 18S-rRNA, added at 500-fold excess).
S. Kafert et al./FEBS Letters 421 (1998) 2^6 5
Acknowledgements: This work was supported by grants from the
Deutsche Forschungsgemeinschaft (SFB244/B15) and from the Ger-
man Federal Ministry for Education, Science, Research and Technol-
ogy.
References
[1] Ross, J. (1995) Microbiol. Rev. 59, 423^450.
[2] Chen, F.Y., Amara, F.M. and Wright, J.A. (1994) Biochem. J.
302, 125^132.
[3] Amara, F.M., Chen, F.Y. and Wright, J.A. (1994) EMBO J. 12,
3977^3986.
[4] Amara, F.M., Chen, F.Y. and Wright, J.A. (1995) Nucleic Acids
Res. 23, 1461^1467.
[5] Hentze, M.W. and Kuºhn, L.C. (1996) Proc. Natl. Acad. Sci.
USA 93, 8175^8182.
[6] Binder, R., Hwang, S.-P.L., Ratnasabapathy, R. and Williams,
D.L. (1989) J. Biol. Chem. 264, 16910^16918.
[7] Chen, C.-Y.A. and Shyu, A.-B. (1995) Trends Biochem. Sci. 20,
465^470.
[8] Alberta, J.A., Rundell, K. and Stiles, C.D. (1994) J. Biol. Chem.
269, 4532^4538.
[9] Zhang, W., Wagner, B.J., Ehrenman, K., Schaefer, A.W., de
Maria, C.T., Crater, D., de Haven, K., Long, L. and Brewer,
G. (1993) Mol. Cell. Biol. 13, 7652^7665.
[10] King, P.H., Levine, T.D., Fremeau, R.T. and Keene, J.D. (1994)
J. Neurosci. 14, 1943^1952.
[11] Nakagawa, J., Waldner, H., Meyer-Monard, S., Hofsteenge, J.,
Jenoº, P. and Moroni, C. (1995) Proc. Natl. Acad. Sci. USA 92,
2051^2055.
[12] Myer, V.E., Fan, X.C. and Steitz, J.A. (1997) EMBO J. 16, 2130^
2139.
[13] Winzen, R., Kafert, S., PreiM, B., Mylius-Spencker, H., Resch, K.
and Holtmann, H. (1996) J. Biol. Chem. 270, 13461^13467.
[14] Vandenabeele, P., Declerq, W., Beyaert, R. and Fiers, W. (1995)
Trends Cell Biol. 5, 392^399.
[15] Boldin, M.P., Mett, I.L., Varfolomeev, E.E., Chumakov, I.,
Shemer-Avni, Y., Camonis, J.H. and Wallach, D. (1995) J. Biol.
Chem. 270, 387^391.
[16] Winzen, R., Wallach, D., Engelmann, H., Nophar, Y., Brake-
busch, C., Kemper, O., Resch, K. and Holtmann, H. (1992)
J. Immunol. 148, 3454^3460.
[17] Dwyer, K.J., Boado, R.J. and Pardridge, W.M. (1996) J. Neuro-
chem. 66, 449^458.
[18] Tsukamoto, H., Boado, R.J. and Pardridge, W.M. (1996) J. Clin.
Invest. 97, 2823^2832.
[19] Tsukamoto, H., Boado, R.J. and Pardridge, W.M. (1997) J. Neu-
rochem. 68, 2587^2592.
[20] Sundstrom, C. and Nilsson, K. (1976) Int. J. Cancer 17, 565^577.
[21] Nophar, Y., Kemper, O., Brakenbusch, C., Engelmann, H.,
Zwang, R., Aderka, D., Holtmann, H. and Wallach, D. (1990)
EMBO J. 9, 3269^3278.
[22] Stephens, J.M., Carter, B.Z., Pekala, P.H. and Malter, J.S. (1992)
J. Biol. Chem. 267, 8336^8341.
[23] Fukuzumi, M., Shinomiya, H., Shimizu, Y., Ohishi, K. and Ut-
sumi, S. (1996) Infect. Immun. 64, 108^112.
[24] Cornelius, P., Marlowe, M., Lee, M.D. and Pekala, P.H. (1990)
J. Biol. Chem. 265, 20506^20516.
[25] McGowan, K., Long, S.D. and Pekala, P.H. (1995) Pharmacol.
Ther. 66, 465^505.
[26] Jain, R.G., Andrews, L.G., McGowan, K.M., Pekala, P.H. and
Keene, J.D. (1997) Mol. Cell. Biol. 17, 954^962.
FEBS 19669 8-1-98
S. Kafert et al./FEBS Letters 421 (1998) 2^66
